{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:02:44Z","timestamp":1790337764676,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012527","name":"Ministry of Higher Education Science Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012527","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vascn.2026.108565","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:06:18Z","timestamp":1784559978000},"page":"108565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In silico study: ADMET-driven pharmacokinetic profiling of antiviral compounds for pre-clinical screening framework of intranasal drug development"],"prefix":"10.1016","volume":"140","author":[{"given":"Jeerakit","family":"Kerdsiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasana","family":"Pitaksuteepong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitra","family":"Nuengchamnong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kowit","family":"Hengphasatporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwaporn","family":"Boonyasuppayakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvapan","family":"Bhattarakosol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuteru","family":"Shigeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimar","family":"Loebenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neti","family":"Waranuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2026.108565_bb0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2015.06.017","article-title":"Towards antivirals against chikungunya virus","volume":"121","author":"Abdelnabi","year":"2015","journal-title":"Antiviral Research"},{"issue":"3","key":"10.1016\/j.vascn.2026.108565_bb0010","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.eplepsyres.2013.02.018","article-title":"A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers","volume":"105","author":"Agarwal","year":"2013","journal-title":"Epilepsy Research"},{"issue":"12","key":"10.1016\/j.vascn.2026.108565_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122680","article-title":"Enhanced nasal deposition and anti-coronavirus effect of favipiravir-loaded mucoadhesive chitosan\u2013alginate nanoparticles","volume":"14","author":"Alcantara","year":"2022","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.vascn.2026.108565_bb0020","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1039\/c1md00093d","article-title":"Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space","volume":"2","author":"Alex","year":"2011","journal-title":"MedChemComm"},{"issue":"11","key":"10.1016\/j.vascn.2026.108565_bb0025","doi-asserted-by":"crossref","first-page":"11169","DOI":"10.1007\/s11033-022-07822-2","article-title":"Nitazoxanide and COVID-19: A review","volume":"49","author":"Al-Kuraishy","year":"2022","journal-title":"Molecular Biology Reports"},{"issue":"5","key":"10.1016\/j.vascn.2026.108565_bb0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/10717540802035251","article-title":"Acyclovir liposomes for intranasal systemic delivery: Development and pharmacokinetics evaluation","volume":"15","author":"Alsarra","year":"2008","journal-title":"Drug Delivery"},{"key":"10.1016\/j.vascn.2026.108565_bb0035","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.2147\/IJN.S313093","article-title":"Clinical, biochemical and molecular evaluations of Ivermectin Mucoadhesive Nanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19","volume":"16","author":"Aref","year":"2021","journal-title":"International Journal of Nanomedicine"},{"issue":"12","key":"10.1016\/j.vascn.2026.108565_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12121230","article-title":"Intranasal Nanoemulsions for direct nose-to-brain delivery of actives for CNS disorders","volume":"12","author":"Bahadur","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/17425247.2012.636801","article-title":"Physicochemical and physiological considerations for efficient nose-to-brain targeting","volume":"9","author":"Bahadur","year":"2012","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.vascn.2026.108565_bb0050","series-title":"Nasal drug delivery","first-page":"43","article-title":"Factors affecting the Design of Nasal Drug Delivery System","author":"Bassi da Silva","year":"2023"},{"issue":"5","key":"10.1016\/j.vascn.2026.108565_bb0055","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/cpt.1402","article-title":"Imaging P-glycoprotein function at the blood-brain barrier as a determinant of the variability in response to central nervous system drugs","volume":"105","author":"Bauer","year":"2019","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-409X(97)00063-X","article-title":"Effects of physicochemical properties and other factors on systemic nasal drug delivery","volume":"29","author":"Behl","year":"1998","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.vascn.2026.108565_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.132652","article-title":"In silico detection of potential inhibitors from vitamins and their derivatives compounds against SARS-CoV-2 main protease by using molecular docking, molecular dynamic simulation and ADMET profiling","volume":"1258","author":"Belhassan","year":"2022","journal-title":"Journal of Molecular Structure"},{"issue":"12","key":"10.1016\/j.vascn.2026.108565_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190319","article-title":"Predicting apparent passive permeability of Caco-2 and MDCK cell-monolayers: A mechanistic model","volume":"12","author":"Bittermann","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vascn.2026.108565_bb0075","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.bpj.2014.06.024","article-title":"A method to predict blood-brain barrier permeability of drug-like compounds using molecular dynamics simulations","volume":"107","author":"Carpenter","year":"2014","journal-title":"Biophysical Journal"},{"issue":"Suppl. 1","key":"10.1016\/j.vascn.2026.108565_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clinical Pharmacokinetics"},{"issue":"23","key":"10.1016\/j.vascn.2026.108565_bb0085","doi-asserted-by":"crossref","first-page":"14667","DOI":"10.3390\/ijms232314667","article-title":"Regulation of P-glycoprotein in the brain","volume":"23","author":"Chai","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1016\/j.vascn.2026.108565_bb0090","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1310\/0873-BVDP-AKAY-445U","article-title":"Intracellular concentration of protease inhibitors in HIV-1-infected patients: Correlation with MDR-1 gene expression and low dose of ritonavir","volume":"3","author":"Chaillou","year":"2002","journal-title":"HIV Clinical Trials"},{"issue":"5","key":"10.1016\/j.vascn.2026.108565_bb0095","first-page":"1023","article-title":"Lopinavir\/ritonavir in the treatment of HIV-1 infection: A review","volume":"4","author":"Chandwani","year":"2008","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/A:1023030210154","article-title":"Enhancement of nasal absorption of acyclovir via Cyclodextrins","volume":"44","author":"Chavanpatil","year":"2002","journal-title":"Journal of Inclusion Phenomena and Macrocyclic Chemistry"},{"issue":"11","key":"10.1016\/j.vascn.2026.108565_bb0105","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2174\/15680266113139990033","article-title":"In silico ADMET prediction: Recent advances, current challenges and future trends","volume":"13","author":"Cheng","year":"2013","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.vascn.2026.108565_bb0110","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/adc.64.4.546","article-title":"Measurement of nasal mucociliary clearance","volume":"64","author":"Corbo","year":"1989","journal-title":"Archives of Disease in Childhood"},{"issue":"8","key":"10.1016\/j.vascn.2026.108565_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ph14080711","article-title":"In vitro studies on nasal formulations of nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN)","volume":"14","author":"Costa","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Scientific Reports"},{"issue":"8","key":"10.1016\/j.vascn.2026.108565_bb0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1208\/s12249-024-02986-5","article-title":"Advancements in antiviral therapy: Favipiravir sodium in nasal formulation","volume":"25","author":"Darne","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0130","doi-asserted-by":"crossref","DOI":"10.1093\/rpsppr\/rqac003","article-title":"Formulation, design and strategies for efficient nanotechnology-based nasal delivery systems","volume":"1","author":"De Barros","year":"2022","journal-title":"RPS Pharmacy and Pharmacology Reports"},{"issue":"6","key":"10.1016\/j.vascn.2026.108565_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16060776","article-title":"Predicting ADMET properties from molecule SMILE: A bottom-up approach using attention-based graph neural networks","volume":"16","author":"De Carlo","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vascn.2026.108565_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101755","article-title":"An update on SARS-CoV-2\/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies","volume":"37","author":"Dhama","year":"2020","journal-title":"Travel Medicine and Infectious Disease"},{"issue":"14","key":"10.1016\/j.vascn.2026.108565_bb0145","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3109\/08958378.2015.1066903","article-title":"Gene expression and immunochemical localization of major cytochrome P450 drug-metabolizing enzymes in bovine nasal olfactory and respiratory mucosa","volume":"27","author":"Dhamankar","year":"2015","journal-title":"Inhalation Toxicology"},{"key":"10.1016\/j.vascn.2026.108565_bb0150","series-title":"Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization","author":"Di","year":"2016"},{"key":"10.1016\/j.vascn.2026.108565_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104148","article-title":"Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2","volume":"82","author":"Driouich","year":"2022","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.vascn.2026.108565_bb0160","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00003495-199958040-00016","article-title":"Zanamivir: A review of its use in influenza","volume":"58","author":"Dunn","year":"1999","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bpj.2016.11.900","article-title":"A model for the transient subdiffusive behavior of particles in mucus","volume":"112","author":"Ernst","year":"2017","journal-title":"Biophysical Journal"},{"issue":"6","key":"10.1016\/j.vascn.2026.108565_bb0170","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.xphs.2021.01.017","article-title":"Safety and pharmacokinetic assessments of a novel Ivermectin nasal spray formulation in a pig model","volume":"110","author":"Errecalde","year":"2021","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"9","key":"10.1016\/j.vascn.2026.108565_bb0175","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.200160","article-title":"Cytokine storm and COVID-19: A chronicle of pro-inflammatory cytokines","volume":"10","author":"Fara","year":"2020","journal-title":"Open Biology"},{"key":"10.1016\/j.vascn.2026.108565_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.708364","article-title":"In silico pharmacokinetics, ADMET study and conceptual DFT analysis of two plant Cyclopeptides isolated from Rosaceae as a computational Peptidology approach","volume":"9","author":"Flores-Holgu\u00edn","year":"2021","journal-title":"Frontiers in Chemistry"},{"issue":"W1","key":"10.1016\/j.vascn.2026.108565_bb0185","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: An updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Research"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12010079","article-title":"Comparison of various cell lines and three-dimensional Mucociliary tissue model systems to estimate drug permeability using an in vitro transport study to predict nasal drug absorption in rats","volume":"12","author":"Furubayashi","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.vascn.2026.108565_bb0195","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Research"},{"issue":"18","key":"10.1016\/j.vascn.2026.108565_bb0200","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMcp2009249","article-title":"Mild or moderate Covid-19","volume":"383","author":"Gandhi","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.vascn.2026.108565_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030113","article-title":"Strategies to enhance drug absorption via nasal and pulmonary routes","volume":"11","author":"Ghadiri","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0210","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0168-3659(87)90089-7","article-title":"Physicochemical determinants of nasal drug absorption","volume":"6","author":"Gibson","year":"1987","journal-title":"Journal of Controlled Release"},{"issue":"8","key":"10.1016\/j.vascn.2026.108565_bb0215","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1023\/A:1025053115583","article-title":"P-glycoprotein attenuates brain uptake of substrates after nasal instillation","volume":"20","author":"Graff","year":"2003","journal-title":"Pharmaceutical Research"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0220","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory syncytial virus: Infection, detection, and new options for prevention and treatment","volume":"30","author":"Griffiths","year":"2017","journal-title":"Clinical Microbiology Reviews"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome P450 and chemical toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chemical Research in Toxicology"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/bbrc.1997.7775","article-title":"Evidence for CYP2D6 expression in human lung","volume":"241","author":"Guidice","year":"1997","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.vascn.2026.108565_bb0235","series-title":"Drug delivery: Principles and applications","first-page":"1","article-title":"Factors that impact the developability of drug candidates: An overview","author":"Han","year":"2005"},{"issue":"6","key":"10.1016\/j.vascn.2026.108565_bb0240","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00003088-198611060-00005","article-title":"Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship","volume":"11","author":"Holford","year":"1986","journal-title":"Clinical Pharmacokinetics"},{"issue":"1\u20133","key":"10.1016\/j.vascn.2026.108565_bb0245","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery--possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"Journal of Controlled Release"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0250","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/js9803205","article-title":"MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening","volume":"88","author":"Irvine","year":"1999","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"9","key":"10.1016\/j.vascn.2026.108565_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/cells9092100","article-title":"Ivermectin as a broad-Spectrum host-directed antiviral: The real Deal?","volume":"9","author":"Jans","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.vascn.2026.108565_bb0260","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1097\/00002030-200107270-00004","article-title":"P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: Potential for accelerated viral drug resistance?","volume":"15","author":"Jones","year":"2001","journal-title":"Aids"},{"key":"10.1016\/j.vascn.2026.108565_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113058","article-title":"Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro","volume":"150","author":"Jonsdottir","year":"2022","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.vascn.2026.108565_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09925","article-title":"Nose to brain delivery of nanosuspensions with first line antiviral agents is alternative treatment option to neuro-AIDS treatment","volume":"8","author":"Kakad","year":"2022","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.vascn.2026.108565_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2123","article-title":"Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection","volume":"30","author":"Keam","year":"2020","journal-title":"Reviews in Medical Virology"},{"issue":"21","key":"10.1016\/j.vascn.2026.108565_bb0280","doi-asserted-by":"crossref","first-page":"14261","DOI":"10.1021\/acs.jmedchem.2c01147","article-title":"Hydrogen-bond donors in drug design","volume":"65","author":"Kenny","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"issue":"13","key":"10.1016\/j.vascn.2026.108565_bb0285","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","article-title":"Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918","volume":"20","author":"Kruijtzer","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0290","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/biom14010099","article-title":"A review of CYP-mediated drug interactions: Mechanisms and in vitro drug-drug interaction assessment","volume":"14","author":"Lee","year":"2024","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.vascn.2026.108565_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040559","article-title":"Dual inhibition of P-gp and BCRP improves Oral Topotecan bioavailability in rodents","volume":"13","author":"Lee","year":"2021","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.vascn.2026.108565_bb0300","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nature Reviews Drug Discovery"},{"issue":"7","key":"10.1016\/j.vascn.2026.108565_bb0305","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.2042-7158.1997.tb06084.x","article-title":"Human jejunal effective permeability and its correlation with preclinical drug absorption models","volume":"49","author":"Lennern\u00e4s","year":"1997","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.vascn.2026.108565_bb0310","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2017.03.002","article-title":"Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses","volume":"142","author":"Leyva-Grado","year":"2017","journal-title":"Antiviral Research"},{"issue":"10340","key":"10.1016\/j.vascn.2026.108565_bb0315","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vascn.2026.108565_bb0320","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cbi.2004.02.003","article-title":"Regulation of cytochrome P450 gene expression in the olfactory mucosa","volume":"147","author":"Ling","year":"2004","journal-title":"Chemico-Biological Interactions"},{"issue":"1\u20133","key":"10.1016\/j.vascn.2026.108565_bb0325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"8","key":"10.1016\/j.vascn.2026.108565_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082119","article-title":"Optimizing absorption for intranasal delivery of drugs targeting the central nervous system using Alkylsaccharide permeation enhancers","volume":"15","author":"Madden","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.vascn.2026.108565_bb0335","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11030-021-10186-7","article-title":"Predicting blood-to-plasma concentration ratios of drugs from chemical structures and volumes of distribution in humans","volume":"25","author":"Mamada","year":"2021","journal-title":"Molecular Diversity"},{"key":"10.1016\/j.vascn.2026.108565_bb0340","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/1177391X0700100003","article-title":"The pK(a) distribution of drugs: Application to drug discovery","volume":"1","author":"Manallack","year":"2007","journal-title":"Perspectives in Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0345","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport--an update","volume":"17","author":"Mao","year":"2015","journal-title":"The AAPS Journal"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32565-w","article-title":"Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates","volume":"13","author":"Marlin","year":"2022","journal-title":"Nature Communications"},{"issue":"7","key":"10.1016\/j.vascn.2026.108565_bb0355","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/jps.2600760709","article-title":"Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity","volume":"76","author":"McMartin","year":"1987","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.vascn.2026.108565_bb0360","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jconrel.2025.01.044","article-title":"Intranasal liposomal remdesivir induces SARS-CoV-2 clearance in K18-hACE2 mice and ensures survival","volume":"379","author":"Mendes","year":"2025","journal-title":"Journal of Controlled Release"},{"issue":"9","key":"10.1016\/j.vascn.2026.108565_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16091125","article-title":"Development of an intranasal in situ system for ribavirin delivery: In vitro and in vivo evaluation","volume":"16","author":"Mikhel","year":"2024","journal-title":"Pharmaceutics"},{"issue":"22","key":"10.1016\/j.vascn.2026.108565_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25225340","article-title":"Molecular modeling to estimate the diffusion coefficients of drugs and other small molecules","volume":"25","author":"Miyamoto","year":"2020","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.vascn.2026.108565_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128794","article-title":"The intranasal application of Zanamivir and carrageenan is synergistically active against influenza A virus in the murine model","volume":"10","author":"Morokutti-Kurz","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vascn.2026.108565_bb0380","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10822-011-9478-1","article-title":"Qualitative prediction of blood\u2013brain barrier permeability on a large and refined dataset","volume":"25","author":"Muehlbacher","year":"2011","journal-title":"Journal of Computer-Aided Molecular Design"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/v16010152","article-title":"Probenecid inhibits influenza A(H5N1) and A(H7N9) viruses in vitro and in mice","volume":"16","author":"Murray","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.vascn.2026.108565_bb0390","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8198963","article-title":"Cytokine storm in COVID-19 patients, its impact on organs and potential treatment by QTY code-designed detergent-free chemokine receptors","volume":"2020","author":"Mustafa","year":"2020","journal-title":"Mediators of Inflammation"},{"issue":"4","key":"10.1016\/j.vascn.2026.108565_bb0395","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3797\/scipharm.1105-09","article-title":"Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs","volume":"79","author":"Nanjwade","year":"2011","journal-title":"Scientia Pharmaceutica"},{"key":"10.1016\/j.vascn.2026.108565_bb0400","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2017.12.002","article-title":"Technological strategies to estimate and control diffusive passage times through the mucus barrier in mucosal drug delivery","volume":"124","author":"Newby","year":"2018","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"7","key":"10.1016\/j.vascn.2026.108565_bb0405","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13071103","article-title":"Pharmaceutical formulations with P-glycoprotein inhibitory effect as promising approaches for enhancing oral drug absorption and bioavailability","volume":"13","author":"Nguyen","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.vascn.2026.108565_bb0410","first-page":"233","article-title":"Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy","volume":"37","author":"O\u2019Brien","year":"1989","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.vascn.2026.108565_bb0415","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.3390\/molecules14093754","article-title":"Nasal delivery of high molecular weight drugs","volume":"14","author":"Ozsoy","year":"2009","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.vascn.2026.108565_bb0420","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejps.2008.12.011","article-title":"Prediction of drug distribution within blood","volume":"36","author":"Paix\u00e3o","year":"2009","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"4","key":"10.1016\/j.vascn.2026.108565_bb0425","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1021\/mp300547h","article-title":"Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening","volume":"10","author":"Pan","year":"2013","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.vascn.2026.108565_bb0430","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jconrel.2021.05.046","article-title":"Tailoring of P-glycoprotein for effective transportation of actives across blood-brain-barrier","volume":"335","author":"Pathan","year":"2021","journal-title":"Journal of Controlled Release"},{"issue":"3","key":"10.1016\/j.vascn.2026.108565_bb0435","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/pharmaceutics14030588","article-title":"Strategies to improve drug strength in nasal preparations for brain delivery of low aqueous solubility drugs","volume":"14","author":"Pires","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vascn.2026.108565_bb0440","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"Journal of Controlled Release"},{"issue":"12","key":"10.1016\/j.vascn.2026.108565_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082562","article-title":"Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy","volume":"8","author":"Preissner","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vascn.2026.108565_bb0450","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9050436","article-title":"Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm","volume":"9","author":"Rabaan","year":"2021","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.vascn.2026.108565_bb0455","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.166485","article-title":"Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques","volume":"8","author":"Rosenke","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.vascn.2026.108565_bb0460","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: A first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antiviral Research"},{"issue":"9","key":"10.1016\/j.vascn.2026.108565_bb0465","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/hiv.12039","article-title":"Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: A review of pharmacokinetics, case reports and clinical management","volume":"14","author":"Saberi","year":"2013","journal-title":"HIV Medicine"},{"issue":"5","key":"10.1016\/j.vascn.2026.108565_bb0470","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/026119291604400515","article-title":"The adverse outcome pathway for skin sensitisation: Moving closer to replacing animal testing","volume":"44","author":"Schultz","year":"2016","journal-title":"Alternatives to Laboratory Animals"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246007","article-title":"Prediction of nasal spray drug absorption influenced by mucociliary clearance","volume":"16","author":"Shang","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vascn.2026.108565_bb0480","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2133\/dmpk.DMPK-10-RG-108","article-title":"Nasal delivery of P-gp substrates to the brain through the nose-brain pathway","volume":"26","author":"Shingaki","year":"2011","journal-title":"Drug Metabolism and Pharmacokinetics"},{"issue":"15","key":"10.1016\/j.vascn.2026.108565_bb0485","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1021\/acs.jmedchem.5b00201","article-title":"Volume of distribution in drug design","volume":"58","author":"Smith","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"issue":"9","key":"10.1016\/j.vascn.2026.108565_bb0490","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3109\/00498254.2010.500407","article-title":"Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds","volume":"40","author":"Sohlenius-Sternbeck","year":"2010","journal-title":"Xenobiotica"},{"issue":"7","key":"10.1016\/j.vascn.2026.108565_bb0495","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"Pt 2","key":"10.1016\/j.vascn.2026.108565_bb0500","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1113\/jphysiol.2004.068171","article-title":"Regulation of human airway ciliary beat frequency by intracellular pH","volume":"560","author":"Sutto","year":"2004","journal-title":"The Journal of Physiology"},{"issue":"10","key":"10.1016\/j.vascn.2026.108565_bb0505","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1007\/s13346-025-01843-7","article-title":"Unlocking the potential of remdesivir: Innovative approaches to drug delivery","volume":"15","author":"Taha","year":"2025","journal-title":"Drug Delivery and Translational Research"},{"issue":"5","key":"10.1016\/j.vascn.2026.108565_bb0510","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/095632020101200501","article-title":"Mechanisms of action of ribavirin in antiviral therapies","volume":"12","author":"Tam","year":"2001","journal-title":"Antiviral Chemistry and Chemotherapy"},{"key":"10.1016\/j.vascn.2026.108565_bb0515","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.855496","article-title":"Molnupiravir and its antiviral activity against COVID-19","volume":"13","author":"Tian","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/j.vascn.2026.108565_bb0520","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01706354","article-title":"Gentamicin volume of distribution in critically ill septic patients","volume":"16","author":"Triginer","year":"1990","journal-title":"Intensive Care Medicine"},{"issue":"5\u20136","key":"10.1016\/j.vascn.2026.108565_bb0525","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/bdd.711","article-title":"Prediction of human blood-to-plasma drug concentration ratio","volume":"31","author":"Uchimura","year":"2010","journal-title":"Biopharmaceutics & Drug Disposition"},{"issue":"11","key":"10.1016\/j.vascn.2026.108565_bb0530","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","article-title":"Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives","volume":"57","author":"Ugwoke","year":"2005","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0535","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357011775145","article-title":"The biopharmaceutical aspects of nasal mucoadhesive drug delivery","volume":"53","author":"Ugwoke","year":"2001","journal-title":"The Journal of Pharmacy and Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2026.108565_bb0540","first-page":"93","article-title":"The influence of the pH and osmotic pressure upon tracheal ciliary beat frequency as determined with a new photo-electric registration device","volume":"18","author":"Van de Donk","year":"1980","journal-title":"Rhinology"},{"issue":"12","key":"10.1016\/j.vascn.2026.108565_bb0545","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"Journal of Medicinal Chemistry"},{"issue":"16","key":"10.1016\/j.vascn.2026.108565_bb0550","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.4155\/fmc.11.149","article-title":"Drug-permeability and transporter assays in Caco-2 and MDCK cell lines","volume":"3","author":"Volpe","year":"2011","journal-title":"Future Medicinal Chemistry"},{"issue":"3","key":"10.1016\/j.vascn.2026.108565_bb0555","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/carcin\/22.3.481","article-title":"Cytochrome P450 expression and related metabolism in human buccal mucosa","volume":"22","author":"Vondracek","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.vascn.2026.108565_bb0560","series-title":"Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)","author":"Wan","year":"2020"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0565","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1186\/s40001-025-03516-0","article-title":"The role of virus in nasal inflammation","volume":"30","author":"Wang","year":"2025","journal-title":"European Journal of Medical Research"},{"issue":"3","key":"10.1016\/j.vascn.2026.108565_bb0570","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/17460441003605098","article-title":"Lipophilicity in drug discovery","volume":"5","author":"Waring","year":"2010","journal-title":"Expert Opinion on Drug Discovery"},{"issue":"7","key":"10.1016\/j.vascn.2026.108565_bb0575","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0580","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.vascn.2026.108565_bb0585","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.vascn.2026.108565_bb0590","series-title":"Nasal Drug Delivery","first-page":"1","article-title":"An overview of the anatomy and physiology of nasal passage from drug delivery point of view","author":"Yadav","year":"2023"},{"issue":"6","key":"10.1016\/j.vascn.2026.108565_bb0595","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option","volume":"92","author":"Yao","year":"2020","journal-title":"Journal of Medical Virology"},{"issue":"5","key":"10.1016\/j.vascn.2026.108565_bb0600","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s004280050359","article-title":"Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues","volume":"434","author":"Yokose","year":"1999","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.vascn.2026.108565_bb0605","first-page":"1","article-title":"The effectiveness of oseltamivir nanosuspension as a promising intranasal mucoadhesive spray for management of seasonal influenza in infected patients","volume":"16","author":"Zaki","year":"2026","journal-title":"Current Nanomedicine"},{"issue":"1","key":"10.1016\/j.vascn.2026.108565_bb0610","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacology & Therapeutics"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926001589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926001589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:21:50Z","timestamp":1790335310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871926001589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":122,"alternative-id":["S1056871926001589"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108565","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico study: ADMET-driven pharmacokinetic profiling of antiviral compounds for pre-clinical screening framework of intranasal drug development","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108565"}}